Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 20/20 | 0.48 |
| ▸ | KDR | P35968 | 5/20 | 0.48 |
| ▸ | RAF1 | P04049 | 3/20 | 0.42 |
| ▸ | YES1 | P07947 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2858960 | 0.99 | BRAF (0.47) | BRAFKDRRAF1YES1CYP2C9 | |
| SCHEMBL2864269 | 0.95 | BRAF (0.48) | BRAFKDRRAF1YES1CYP2C9 | |
| SCHEMBL2851257 | 0.94 | BRAF (0.49) | BRAFKDRRAF1YES1CYP2C9 | |
| SCHEMBL2857525 | 0.92 | BRAF (0.47) | BRAFKDRRAF1YES1CYP2C9 | |
| SCHEMBL13166458 | 0.92 | BRAF (0.51) | BRAFKDRRAF1YES1CYP2C9 | |
| SCHEMBL13354107 | 0.92 | BRAF (0.47) | BRAFKDRRAF1YES1CYP2C9 | |
| SCHEMBL2853454 | 0.92 | BRAF (0.50) | BRAFKDRRAF1 | |
| Hydrochloric Acid SCHEMBL2855472 | 0.91 | BRAF (0.50) | BRAFKDRRAF1YES1CYP2C9 | |
| SCHEMBL13166459 | 0.91 | BRAF (0.49) | BRAFKDRRAF1YES1CYP2C9 | |
| SCHEMBL2858508 | 0.91 | BRAF (0.49) | BRAFKDRRAF1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8344135-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-01-01 | — | — | US | disclosed |
| US-8344135-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-01-01 | — | — | US | disclosed |
| US-20100249119-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-30 | — | — | US | disclosed |
| US-20100249119-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249119-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | BRAF, NRAS, RAF1 | BRAF 1/4885KDR 983/4885RAF1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.